Navigating the MedTech Maze: New Guide Tackles AI, FDA, and IP

PHOENIXVILLE, Pa. – February 10, 2026 – As medical device innovators grapple with a landscape being rapidly reshaped by artificial intelligence, shifting regulatory goalposts, and complex intellectual property laws, a newly updated resource aims to provide a clear path forward. Facet Life Sciences, a regulatory and product development strategy firm, has announced the publication of the second edition of FDA and Intellectual Property Strategies for Medical Device Technologies, a comprehensive guide featuring insights from six of the company's experts.

The release comes at a critical time for the MedTech industry. The journey from a promising concept to a commercialized medical device has become increasingly fraught with challenges that did not exist even a few years ago. This updated edition, published by Springer International Publishing, directly addresses these new realities, offering a modern playbook for developers navigating the intricate, high-stakes process of bringing new technologies to the U.S. market.

A Landscape in Flux: The New Hurdles for Device Innovators

The most significant driver of change in the medical device sector is the integration of Artificial Intelligence (AI) and Machine Learning (ML). These technologies promise to revolutionize diagnostics, treatment, and patient monitoring, but they also challenge the foundations of traditional regulatory oversight. The U.S. Food and Drug Administration (FDA), which has authorized over 1,000 AI/ML-enabled medical devices to date, is racing to adapt its frameworks.

In response to the dynamic nature of AI, which can learn and evolve after deployment, the FDA has moved beyond its static product review models. A key development is the finalization of guidance for Predetermined Change Control Plans (PCCPs), which allow manufacturers to pre-specify planned modifications to AI algorithms without requiring a new submission for every update. This framework, outlined in the agency's 2021 AI/ML-Based Software as a Medical Device (SaMD) Action Plan, is crucial for fostering innovation while ensuring patient safety.

The regulatory environment is also influenced by broader policy. The White House's 2023 Executive Order on AI has pushed federal agencies, including the FDA, to prioritize the development of safe, secure, and trustworthy AI, with a focus on reducing algorithmic bias and increasing transparency. For developers, this translates into more rigorous expectations for data diversity in training models and clearer risk assessments throughout the product lifecycle. Beyond AI, the FDA continues to update its requirements in other key areas, such as making its electronic Submission Template And Resource (eSTAR) mandatory for 510(k) and, more recently, PMA and De Novo submissions, streamlining the review process but also adding a new layer of procedural compliance.

Bridging the Gap Between Regulation and Intellectual Property

Successfully launching a medical device requires more than just regulatory clearance; it demands a savvy intellectual property (IP) strategy that protects the innovation. The second edition of the guide places a renewed emphasis on the critical interplay between these two domains, which are often managed in silos. As technology evolves, so do the rules governing its ownership.

The U.S. Patent and Trademark Office (USPTO) has recently provided crucial clarity on AI-assisted inventions. While reaffirming that only a natural person can be named an inventor, its guidance treats AI systems as sophisticated tools, meaning innovations created with the help of AI are patentable as long as a human has made a significant contribution. This requires meticulous documentation of the inventive process and places a new burden on R&D teams. This clarification signals a more patent-friendly environment for AI, encouraging innovators to pursue aggressive filing strategies.

This evolving IP landscape creates a dual challenge: innovators must secure robust patent protection while simultaneously generating the evidence needed to satisfy the FDA. The strategies for each can sometimes be in conflict. “The journey from medical device concept to commercialization has been significantly impacted by recent key shifts in the technological landscape, including artificial intelligence (AI), the current FDA and political climate, and the ever-evolving intellectual property and US commercial environment,” stated Lisa Jenkins VanLuvanee, Ph.D., Facet’s Chief Operating Officer & VP of Research and Development, in the announcement. The book, co-produced with the intellectual property team at Volpe and Koenig, aims to demystify this connection, providing integrated guidance to prevent costly missteps.

An Updated Playbook for the Modern Developer

The updated guide is designed as a practical resource for the teams on the front lines of innovation—from startups to established R&D departments. It moves beyond theoretical discussions to provide detailed examples of the major hurdles developers commonly face, offering actionable strategies to overcome them. The content is informed by the direct experience of its contributing authors from Facet Life Sciences: Michelle Byrne, William Hodnick, Joshua Eldridge, Randy Goodman, Dana Blue, and Dr. VanLuvanee.

Their collective expertise spans decades in product development, regulatory affairs, and R&D strategy, including work on blockbuster drugs and therapies for rare diseases. The book distills this experience into guidance on crafting regulatory submissions with the FDA reviewer in mind, aiming for fewer questions and faster approvals. By updating the specific regulations and guidances that affect medical device approval, clearance, and commercialization, the text serves as an essential reference for navigating the entire product lifecycle efficiently.

The focus on the interconnectedness of scientific, regulatory, and commercialization disciplines is a hallmark of Facet's approach. The book reflects this philosophy, guiding innovators through early-stage planning, the formal review process, and ultimate market readiness. For any company developing a novel device that challenges precedent, this kind of strategic roadmap is indispensable.

Preparing for Tomorrow's Challenges in MedTech

While addressing current issues, the guide also helps innovators prepare for the next wave of challenges. As medical devices become increasingly connected, cybersecurity has transitioned from an IT issue to a critical component of patient safety and regulatory compliance. The FDA has intensified its oversight, issuing updated guidance that mandates robust security measures be integrated early in the device design process.

Furthermore, the globalization of MedTech introduces another layer of complexity. Companies looking to market their products internationally must navigate disparate regulatory systems. The European Union’s AI Act, for instance, classifies most healthcare AI systems as "high-risk," imposing strict requirements that go beyond existing medical device regulations. Achieving global harmonization remains a long-term goal, meaning developers currently need tailored strategies for each major market.

Other emerging frontiers include the growing reliance on Real-World Evidence (RWE) to support regulatory decisions and the industry-wide push for greater health equity. Ensuring that AI algorithms are free from bias and that digital health technologies are accessible to all populations are becoming core tenets of responsible innovation. Navigating this confluence of advancing technology, expanding regulations, and evolving ethical considerations requires a forward-looking strategy, reinforcing the need for expert, up-to-date guidance to bring the next generation of life-saving medical devices to patients safely and efficiently.